The 36-month beta value for ENLV is at 1.23. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ENLV is 14.97M, and currently, shorts hold a 1.58% of that float. The average trading volume for ENLV on April 25, 2024 was 171.78K shares.
ENLV) stock’s latest price update
The stock price of Enlivex Therapeutics Ltd (NASDAQ: ENLV) has jumped by 13.64 compared to previous close of 1.32. Despite this, the company has seen a gain of 1.35% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-15 that Enlivex (ENLV) plunges after it shares mixed results from a mid-stage study evaluating its lead drug as a potential treatment for sepsis.
ENLV’s Market Performance
Enlivex Therapeutics Ltd (ENLV) has seen a 1.35% rise in stock performance for the week, with a -63.50% decline in the past month and a -50.00% plunge in the past quarter. The volatility ratio for the week is 9.52%, and the volatility levels for the past 30 days are at 14.22% for ENLV. The simple moving average for the past 20 days is -47.16% for ENLV’s stock, with a -38.31% simple moving average for the past 200 days.
Analysts’ Opinion of ENLV
Many brokerage firms have already submitted their reports for ENLV stocks, with H.C. Wainwright repeating the rating for ENLV by listing it as a “Buy.” The predicted price for ENLV in the upcoming period, according to H.C. Wainwright is $33 based on the research report published on March 02, 2021 of the previous year 2021.
ENLV Trading at -53.70% from the 50-Day Moving Average
After a stumble in the market that brought ENLV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.32% of loss for the given period.
Volatility was left at 14.22%, however, over the last 30 days, the volatility rate increased by 9.52%, as shares sank -61.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -47.74% lower at present.
During the last 5 trading sessions, ENLV rose by +1.35%, which changed the moving average for the period of 200-days by -37.76% in comparison to the 20-day moving average, which settled at $2.7185. In addition, Enlivex Therapeutics Ltd saw -44.44% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ENLV
The total capital return value is set at -0.82. Equity return is now at value -66.88, with -55.65 for asset returns.
Based on Enlivex Therapeutics Ltd (ENLV), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -67.13. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -57.82.
Currently, EBITDA for the company is -24.09 million with net debt to EBITDA at -0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.57.
Conclusion
In conclusion, Enlivex Therapeutics Ltd (ENLV) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
